GLP-1 Vision Loss Claims: What NAION Lawsuits Allege

A New Injury Claim Emerging in GLP-1 Litigation

Most of the early coverage of GLP-1 injury lawsuits focused on the digestive system — gastroparesis, bowel obstruction, gallbladder disease, and pancreatitis. Over the past year, a different category of claim has appeared in news reports: sudden, often permanent vision loss attributed to a condition called NAION.

News outlets have reported individual lawsuits filed by people who say they lost vision in one eye while taking a GLP-1 medication. One report described a Georgia woman participating in litigation claiming a link between GLP-1 weight loss drugs and blindness. Legal commentary has also discussed similar claims involving liraglutide products such as Saxenda.

These are allegations. No court has determined that any GLP-1 medication causes NAION, and the manufacturers dispute the claims. What follows is an explanation of the condition, what the published research actually reports, and what people who have experienced sudden vision loss should understand.

What NAION Actually Is

NAION stands for non-arteritic anterior ischemic optic neuropathy. It is an injury to the optic nerve — the bundle of fibers that carries visual signals from the eye to the brain — caused by an interruption in blood supply to the front portion of that nerve.

Some features that make NAION distinctive:

• It typically comes on suddenly and painlessly, often noticed on waking.
• It usually affects one eye first, though the second eye can be affected later.
• The vision loss is frequently described as a dark area, curtain, or missing section in part of the visual field, commonly the upper or lower half.
• There is no widely accepted treatment that reliably restores lost vision, and damage is often permanent.

Because NAION is an optic nerve condition rather than a problem with the eye’s lens or retina, glasses do not correct it. General background on optic nerve and neurological conditions is available through the National Institute of Neurological Disorders and Stroke.

Who Is Already at Higher Risk

NAION is not exclusively associated with medication use. Ophthalmology literature has long described several background risk factors, including:

• Diabetes
• High blood pressure
• Sleep apnea
• High cholesterol
• A particular optic disc anatomy sometimes called a “crowded” or “disc at risk”

This matters for anyone evaluating a possible claim. Many people prescribed GLP-1 medications have type 2 diabetes or obesity-related conditions, which are themselves associated with NAION. Separating background risk from any medication-associated risk is one of the central scientific disputes in this litigation, and it is a question that will be argued by expert witnesses on both sides.

For general information on diabetes and its complications, the National Institute of Diabetes and Digestive and Kidney Diseases maintains patient-facing resources.

What the Published Research Reports

The scientific attention to this issue traces largely to a 2024 study published in JAMA Ophthalmology by researchers affiliated with Mass Eye and Ear, which reported a statistical association between semaglutide prescriptions and a higher rate of NAION diagnoses in the patient population they reviewed.

Several points deserve emphasis:

• The study reported an association, not proof of causation. Observational research of this kind can identify a signal worth investigating; it cannot by itself establish that a drug caused a specific person’s injury.
• The research drew from a single institution’s patient records, which the authors themselves noted as a limitation.
• Subsequent analyses using other datasets have been published, and researchers have not reached uniform conclusions.

Anyone who wants to read the underlying literature directly — including the original study and the responses to it — can search the abstracts through PubMed, the National Library of Medicine’s index of published medical research. Reading the primary sources is often more useful than reading summaries of them.

The Regulatory Picture

Drug labeling changes and safety communications are the clearest official signals about a recognized risk, and they are also frequently misreported.

Rather than rely on secondhand summaries, patients and family members should check the current, official prescribing information and any safety communications directly through the U.S. Food and Drug Administration. Drug labels are updated over time, and what appears in a label today may differ from what appeared when a given prescription was written — a distinction that matters a great deal in failure-to-warn litigation.

Regulatory reviews of the NAION signal have been reported and discussed in the medical press. We do not characterize the outcome of any specific review here, because the official record is the only reliable source for that.

What Plaintiffs Are Alleging

The lawsuits reported so far generally center on failure to warn theories. In broad terms, plaintiffs allege that:

• The manufacturers knew or should have known of a potential association between their GLP-1 products and NAION.
• The product labeling and prescribing information did not adequately communicate that potential risk to patients and prescribing physicians.
• Had an adequate warning existed, the patient or their doctor might have made a different treatment decision, sought earlier evaluation of visual symptoms, or monitored differently.

Manufacturers dispute these allegations. In defending pharmaceutical claims, companies typically argue that the science does not establish causation, that background conditions explain the injury, and that their warnings were adequate and approved by regulators.

Nothing about the existence of a lawsuit establishes fault. Courts resolve these questions through evidence, expert testimony, and eventually trials.

How These Cases Get Organized

When many similar federal lawsuits are filed against the same defendants over the same product, they may be consolidated for pretrial proceedings into a multidistrict litigation, or MDL. That process is managed by the Judicial Panel on Multidistrict Litigation, and general background on how federal courts operate is available at uscourts.gov.

One point is worth stating plainly because it is so often misunderstood in headlines: consolidation is a case-management decision, not a ruling on the merits. When a panel groups cases together, it is deciding that shared pretrial work is efficient. It is not finding that the drug caused anyone’s injury, and it is not a signal about how the cases will ultimately resolve.

The same is true of scheduling orders, discovery disputes, and hearing dates. They move a case forward procedurally; they do not decide whether a claim is valid.

Symptoms That Warrant Immediate Medical Attention

If you experience any of the following, seek emergency evaluation — this is a medical matter first and a legal matter second:

• Sudden loss or dimming of vision in one eye
• A dark shadow, curtain, or blind spot blocking part of your visual field
• Sudden blurring that does not resolve within minutes
• Vision changes accompanied by headache, jaw pain, or scalp tenderness (these may point to a different, urgent condition requiring immediate treatment)

Do not wait for a scheduled appointment. An ophthalmologist or neuro-ophthalmologist can examine the optic nerve and document what is found. That documentation — the exam findings, imaging, and visual field testing — becomes the medical record any future claim would depend on.

If You Are Considering a Claim

A few practical notes for anyone evaluating their situation:

Records matter more than anything else. Pharmacy records showing which product you took and when, ophthalmology records documenting the diagnosis, and your broader medical history all bear directly on whether a claim can be evaluated.

Deadlines are real and unforgiving. Every state sets its own statute of limitations for product liability claims, and missing it generally ends the claim regardless of its merits. General background on limitations periods is available through the Legal Information Institute.

Do not stop a prescribed medication based on a news article. GLP-1 medications are prescribed for serious conditions, and stopping abruptly carries its own risks. Any change should be a conversation with your prescriber.

If you are researching digestive injuries rather than vision loss, our GLP-1 and Ozempic litigation page covers those claims as well.

Take the Next Step

If you or someone in your family was diagnosed with NAION or another form of sudden vision loss while taking a GLP-1 medication, you can request a free, confidential case review. There is no cost to have your situation evaluated and no obligation to move forward.

We will listen to what happened, explain how this litigation works, and give you an honest assessment of whether your circumstances fit what these cases require — including when they do not.

Request a free case review to speak with our team.

This article is for general informational purposes and is not medical or legal advice. It does not create an attorney-client relationship. Outcomes in litigation depend on the specific facts of each case, and no result is ever guaranteed.